This company has been marked as potentially delisted and may not be actively trading. Aptose Biosciences (APTO) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock APTO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Aptose Biosciences Secures Funding for Drug DevelopmentAugust 25, 2025 | msn.comAptose Biosciences Inc News (APS) - Investing.comAugust 24, 2025 | investing.comAptose’s tuspetinib boosts SoC response in AML trialAugust 19, 2025 | msn.comAptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial ResultsAugust 14, 2025 | msn.comAptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its ShareholdersAugust 1, 2025 | financialpost.comFAptose Biosciences, Inc.: Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AMLJuly 16, 2025 | finanznachrichten.deAptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AMLJuly 15, 2025 | financialpost.comFAptose Upgraded to Trade on OTCQB MarketJuly 1, 2025 | financialpost.comFAptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AMLJune 20, 2025 | financialpost.comFAptose Gets Advance From Chairman and CEO, Warns of Need for FundingJune 17, 2025 | marketwatch.comAptose Provides Corporate UpdatesJune 17, 2025 | financialpost.comFAptose reports promising data from TUS+VEN+AZA therapy for AMLJune 14, 2025 | investing.comAPTOF Aptose Biosciences Inc.June 6, 2025 | seekingalpha.comAptose Reports Promising Data From Phase 1/2 TUSCANY Study Of Tuspetinib-based Triple Drug TherapyMay 7, 2025 | nasdaq.comAptose Biosciences announces change in accounting firmApril 23, 2025 | investing.comAptose Announces Auditor Not Standing for Re-AppointmentApril 23, 2025 | globenewswire.comAptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 23, 2025 | globenewswire.comAptose Biosciences Inc APTOFApril 6, 2025 | morningstar.comMWhy Aptose Biosciences (APTO) Stock Is Down Over 40%April 1, 2025 | benzinga.comAptose Common Shares to Delist from Nasdaq as of April 2, 2025April 1, 2025 | financialpost.comFAptose Biosciences, Inc.: Aptose Reports Year End 2024 Results and Corporate HighlightsMarch 28, 2025 | finanznachrichten.deAptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last yearMarch 28, 2025 | markets.businessinsider.comAptose Biosciences price target raised to $6 from $2 at H.C. WainwrightMarch 28, 2025 | markets.businessinsider.comAptose Reports Year End 2024 Results and Corporate HighlightsMarch 28, 2025 | financialpost.comFAptose Reports Year End 2024 Results and Corporate HighlightsMarch 28, 2025 | globenewswire.comAptose Biosciences Converts Debt to Equity with Hanmi PharmaceuticalMarch 26, 2025 | investing.comAptose Biosciences Regains Nasdaq Bid Price ComplianceMarch 17, 2025 | msn.comAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceMarch 17, 2025 | globenewswire.comAptose Biosciences Inc. (NASDAQ:APTO) Short Interest UpdateFebruary 28, 2025 | marketbeat.comAptose Biosciences initiated with a Speculative Buy at Alliance Global PartnersFebruary 27, 2025 | markets.businessinsider.comAptose Biosciences trading halted, news pendingFebruary 25, 2025 | markets.businessinsider.comAptose Biosciences approved to escalate dose in Phase 1/2 AML trialFebruary 20, 2025 | markets.businessinsider.comAptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortFebruary 20, 2025 | globenewswire.comAptose Biosciences, Inc.: Aptose Announces Reverse Share SplitFebruary 19, 2025 | finanznachrichten.deAptose Biosciences announces 1-for-30 reverse share splitFebruary 19, 2025 | markets.businessinsider.comAptose Announces Reverse Share SplitFebruary 18, 2025 | globenewswire.comAptose Biosciences files to sell 12.03M shares of common stock for holdersFebruary 13, 2025 | markets.businessinsider.comAptose Biosciences secures $25 million equity facilityFebruary 13, 2025 | msn.comAptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityFebruary 13, 2025 | globenewswire.comAptose Biosciences' leukemia drug shows early promiseFebruary 12, 2025 | msn.comAptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialFebruary 12, 2025 | finance.yahoo.comAptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialFebruary 12, 2025 | globenewswire.comAptose Biosciences shareholders approve reverse stock splitJanuary 29, 2025 | msn.comAptose Biosciences faces Nasdaq delisting over share priceJanuary 21, 2025 | msn.comAptose Biosciences Inc APSJanuary 16, 2025 | morningstar.comMAptose Biosciences: Positive Outlook and Buy Rating Backed by Promising Tuspetinib Developments in AML TreatmentJanuary 11, 2025 | markets.businessinsider.comAptose announces first AML patients dosed in TUSCANY trialJanuary 10, 2025 | markets.businessinsider.comAptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialJanuary 9, 2025 | globenewswire.comWall Street Set to Open Lower Friday; Key Inflation Data Lower Than ExpectedDecember 20, 2024 | msn.comAptose Biosciences, Inc.: Aptose Announces Positive Decision by Nasdaq Hearings PanelDecember 20, 2024 | finanznachrichten.de Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APTO Media Mentions By Week APTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.000.72▲Average Medical News Sentiment APTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼01▲APTO Articles Average Week Get the Latest News and Ratings for APTO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aptose Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AIM ImmunoTech News Today NKGen Biotech News Today Calidi Biotherapeutics News Today Prime Medicine News Today Inhibikase Therapeutics News Today Protalix BioTherapeutics News Today CEL-SCI News Today ZIVO Bioscience News Today Invizyne Technologies News Today Cortexyme News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTO Stock Alerts